A candidate tetravalent dengue vaccine is being assessed in three clinical trials involving more than 35,000 children between the ages of 2 and 16 years in the Asia-Pacific and Latin American countries.We report the results of long-term follow-up interim analyses and integrated efficacy analyses.We are assessing the incidence of hospitalization for virologically confirmed dengues a surrogate safety end point during follow-up in years 3–6 of two phase 3 trials,CYD14 and CYD15,and a phase 2b trial,CYD23/57.We estimated vaccine efficacy using pooled data from the first 25 months of CYD14 and CYD15.
展开▼
